Treatment of Pleural Effusion after Lobectomy and Lymphadenectomy for Primary Lung Cancer: A Case Report

Alexei L. Charyshkin, Ekaterina A. Kuzmina, Evgeniy A.Toneev, Bulat I. Khusnutdinov, Aleksander A. Martynov, Vladimir I. Midlenko

International Journal of Biomedicine. 2020;10(1):76-78.
DOI: 10.21103/Article10(1)_CR1
Originally published March 15, 2020


The majority of malignant pleural effusion (MPE) is caused by metastatic disease: most commonly lung cancer in men and breast cancer in women. MPE worsens the quality of life in patients due to the occurrence of respiratory failure, compression of internal organs and violation of homeostasis. Existing methods for MPE treatment have a number of disadvantages, including insufficient analgesia and the use of standard drainage tubes that do not adequately irrigate the pleural space with drugs, thereby reducing the drugs’ effectiveness. The proposed method for the treatment of MPE improves the treatment results by improving the drainage and introduction of drugs into the pleural cavity.

malignant pleural effusions • thoracentesis • pleurodesis
  1. Merabishvili VM, Arseniev AI, Tarkov SA,  Barchuk AA, Shcherbakov AM, Demin EV,  Merabishvili EN.  [Lung cancer morbidity and mortality]. Siberian Journal of Oncology 2018; 17 (6): 15-26. [Article in Russian].
  2. Klimenko VN, Ivanov OV. [Tumor pleurisy: a modern view of the problem]. Grekov's Bulletin of Surgery. 2014;173(2):114-117. [Article in Russian].
  3. Klimenko V.N., Ivanov OV. [Diagnosis and tactics of treatment of tumor pleurisy on an outpatient basis]. Voprosy Onkologii. 2015;61(6):949-955. [Article in Russian].
  4. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189-98. doi: 10.1183/16000617.0019-2016.
  5. Perricone G, Mazzarelli C. Images in clinical medicine. Reexpansion pulmonary edema after thoracentesis. N Engl J Med. 2014;370(12):e19. doi: 10.1056/NEJMicm1309844.
  6. Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 2014;19(6):809-22. doi: 10.1111/resp.12328.
  7. Agarwal R, Khan A, Aggarwal AN, Gupta D. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012;135:297-304.
  8. Plaksin SA, Farshatova LI. A method for the treatment of exudative pleurisy. Patent for Invention RUS No. 2666401. Application No. 2017122884 dated 06/28/2017. Publ. 09/07/2018; bulletin No. 25.[In Russian].
  9. Charyshkin AL, Toneev EA. Results of surgical treatment of lung cancer in patients of different age groups. International Journal of Biomedicine. 2017;7(2):144-146. doi: 10.21103/article7(2)_shc1
  10. Chuchalin AG. Pulmonology: national manual. Brief Edition. M., "Geotar Media"; 2013. [In Russian].
  11. Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One. 2014;9(1):e87060. doi: 10.1371/journal.pone.0087060.
  12. Zhestkov KG, Iaduta RT. [The role and place of talc in malignant pleuritis management (literature review)]. Pirogov Russian Journal of Surgery. 2016;(1):40-44. [Article in Russian].
  13. Clive AO, Bhatnagar R, Psallidas I, Maskell NA. Individualised management of malignant pleural effusion. Lancet Respir Med. 2015;3(7):505-6. doi: 10.1016/S2213-2600(15)00183-6.
  14. Kasapoglu US, Arınç S, Gungor S, Irmak I, Guney P, Aksoy F, et al. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin Respir J. 2016;10(6):791-799. doi: 10.1111/crj.12292.
  15. Thomas R, Fysh ETH, Smith NA, Lee P, Kwan BCH, Yap E, et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.JAMA. 2017;318(19):1903-1912. doi: 10.1001/jama.2017.17426.
  16. Shulutko AM, Ovchinnikov AA, Yasnogorodsky OO, Motus IYa. Endoscopic Thoracic Surgery: A Guide for Physicians. M.: Meditsina; 2006. [In Russian].
  17. Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012 Jun 13;307(22):2383-9. doi: 10.1001/jama.2012.5535.
  18. Charyshkin AL, Toneev EA, Martynov AA, Lisyutin RI, Zul’karnyaev ASh.  Synchronous multiple primary lung cancer: a case report. International Journal of Biomedicine.2018;8(2):162-164 doi: 10.21103/Article8(2)_CR1
  19. Charyshkin AL, Toneev EA, Medvedev АА. [The results of the use of lymphotropic therapy in patients with lung cancer]. Voprpsy Onkologii. 2019;65(1):106-109. [Article in Russian].
  20. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med. 2004;170(4):377-82.
  21. Fysh ETH, Tremblay A, Feller-Kopman D, Mishra EK, Slade M, Garske L, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest. 2013;144(5):1597-1602. doi: 10.1378/chest.12-3103.

Download Article
Received December 23, 2019.
Accepted January 20, 2020.
©2020 International Medical Research and Development Corporation.